跳至主要内容
临床试验/NCT03882866
NCT03882866Unknown不适用

3D-printed Template for Iodine-125 Seed Implantation Therapy in Patients With Locally Advanced Pancreatic Cancer: a Multicenter Study

Ruijin Hospital8 个研究点 分布在 1 个国家目标入组 220 人开始时间: 2019年3月28日最近更新:
适应症

试验速览

阶段
不适用
入组人数
220
试验地点
8
主要终点
Objective Response Rate (ORR)

研究概览

简要总结

This study evaluates the application of 3D-printed template for iodine-125 seed implantation therapy in patients with locally advanced pancreatic cancer. Half of participants will receive 3D-printed coplanar template, while the other half will receive 3D-printed non-coplanar template.

详细描述

Dosimetric verification was performed after implantation. Pre- and postoperative D90, V100, and V150 were calculated. The success rate of iodine-125 seed implantation, dosimetric parameters, objective response rate (ORR),overall survival (OS),toxicities and quality of life of two treatment regimens and complications were analyzed and compared between the two groups.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age: 18-80 years
  • Cytologically or histologically confirmed pancreatic adenocarcinoma
  • Inoperable locally advanced pancreatic cancer based on American Joint Committee on Cancer (AJCC) staging system (8th ed) (without distant metastasis)
  • Single tumor size≤ 6 cm
  • Karnofsky performance score (KPS)≥60
  • Estimated survival ≥3 months
  • Without other several comorbidity
  • Participants must have adequate organ function:
  • WBC≥3×109/L; HGB≥90g/dL; PLT≥50×109/L
  • Aspartate Transaminase (AST)/alanine aminotransferase ( ALT) ≤3 × institutional upper limit of normal
  • Albumin≥3g/dL
  • Total bilirubin ≤3mg/dL
  • PT≤3 × institutional upper limit of normal or INR≤2.3
  • Creatinine ≤1.5 × institutional upper limit of normal
  • Ability to understand and the willingness to sign a written informed consent document

排除标准

  • Patients with other malignant tumors
  • History of other anti-cancer therapy, including surgery,radiation, ablation and so on
  • Pregnant or lactating women
  • Patients with Immunodeficiency disease
  • Several heart disease, for example: New York Heart Association (NYHA) class III/IV congestive heart failure,active coronary heart disease and severe arrhythmia
  • Uncontrolled hypertension
  • Ongoing or active infection (>grade 2 based on National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) 4.0 edition)
  • Active tuberculosis
  • Chronic renal insufficiency
  • Other organ failure
  • History of organ transplantation
  • History of severe mental illness

结局指标

主要结局

Objective Response Rate (ORR)

时间窗: 24 months

ORR is defined as the proportion of the subjects in the analysis population who have a complete response (CR) or partial response (PR). Responses are based on assessments per RECIST 1.1.

次要结局

  • Incidence of treatment-emergent toxicities of two treatment regimens in patients(24 months)
  • Overall Survival (OS)(24 months)
  • Quality of life of two treatment regimens in patients(24 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Zhongmin Wang

Principal Investigator

Ruijin Hospital

研究点 (8)

Loading locations...

相似试验